SCHEMBL25605336

SCHEMBL25605336

CC(C)Oc1cc(-c2cnc(NC(=O)C3CCN(C)CC3)s2)ccc1C#N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.59
▸ GSK3B P49841 7/20 0.54
▸ DYRK1A Q13627 6/20 0.54
▸ WNT1 P04628 4/20 0.54
▸ UCHL1 P09936 2/20 0.50
▸ USP30 Q70CQ3 3/20 0.47
▸ CDK2 P24941 2/20 0.42
▸ CCNE2 O96020 1/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ CCNT1 O60563 1/20 0.41
▸ CCNA2 P20248 1/20 0.41
▸ CCND3 P30281 1/20 0.41
▸ CDK7 P50613 1/20 0.41
▸ CDK9 P50750 1/20 0.41
▸ CCNH P51946 1/20 0.41
▸ MNAT1 P51948 1/20 0.41
▸ CDK6 Q00534 1/20 0.41
▸ CDK5 Q00535 1/20 0.41
▸ CDK5R1 Q15078 1/20 0.41
▸ XDH P47989 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25610896 0.91 MKNK1 (0.61) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25605337 0.86 MKNK1 (0.64) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25610970 0.83 USP30 (0.45) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25610969 0.83 USP30 (0.45) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25613441 0.83 USP30 (0.41) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25611227 0.82 UCHL1 (0.41) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL25611309 0.82 USP30 (0.49) USP30XDH
SCHEMBL17632612 0.81 UCHL1 (0.66) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL29992545 0.81 UCHL1 (0.66) MKNK1GSK3BDYRK1AWNT1UCHL1
SCHEMBL17632608 0.81 UCHL1 (0.66) MKNK1GSK3BDYRK1AWNT1UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 — — US disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B MKNK1 105/4885GSK3B 121/4885DYRK1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback